SCHEDULE 13D/A: Gilead Sciences Solidifies Strategic Stake in Arcus Biosciences, Reaching 35% Ownership

Gilead Sciences, Inc. has significantly increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of strategic share purchases and option exercises, reinforcing their ongoing collaboration.

Summary

• Gilead Sciences, Inc. (Gilead) has reported a beneficial ownership of 39,691,649 shares of Arcus Biosciences, Inc. (Arcus) common stock, representing 35% of the class.
• This ownership includes shares acquired through multiple transactions since 2020, funded by Gilead's available cash resources.
• The most recent acquisition involved 1,363,636 shares purchased in Arcus's public offering on February 18, 2025, at a price of $11.00 per share, totaling $14,999,996.
• Gilead's stake also includes 8,266,889 option shares, which, if immediately exercised, would bring their total ownership to 35% based on 105,137,824 shares outstanding post-public offering.
• The investment is part of a broader Option, License and Collaboration Agreement established in May 2020, granting Gilead exclusive options to acquire licenses to Arcus's clinical programs.
• Gilead has the right to designate three individuals to Arcus's board of directors as part of their Amended and Restated Investor Rights Agreement.
• A 60-day lock-up agreement was entered into by Gilead in connection with the recent public offering, restricting further sales of Arcus shares during this period.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to Gilead's continued and increasing strategic investment in Arcus Biosciences, solidifying a significant ownership stake and reinforcing a long-term collaboration. This indicates strong confidence in Arcus's future prospects and pipeline.

Positives

• Gilead's continued and increasing investment signals strong confidence in Arcus Biosciences' pipeline and strategic direction.
• The long-term collaboration agreement provides Arcus with significant financial backing and validation from a major pharmaceutical company.
• Gilead's right to designate three board members indicates a deep strategic alignment and influence in Arcus's governance.
• The exercise of options to maintain a 35% stake demonstrates Gilead's commitment to its strategic partnership with Arcus.

Negatives

• The recent public offering at $11.00 per share represents a lower price compared to Gilead's previous purchase prices, which ranged from $19.26 to $39.00 per share, potentially indicating a lower market valuation for Arcus at the time of the offering.
• The public offering itself causes dilution for existing shareholders, although Gilead's participation mitigates some of this impact.

Future Outlook

Gilead retains a five-year option to purchase additional shares of Arcus common stock, up to a maximum of 35% of the then-outstanding shares, at a price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) or the initial purchase price of $33.54 per share. This indicates a potential for continued strategic investment and collaboration.

Management Comments

• Gilead's acquisitions of Arcus's securities were effected in connection with the Collaboration Agreement and Equity Agreements, and due to the belief that the securities of the Issuer represent an attractive investment.

Industry Context

This filing highlights a common strategic trend in the biopharmaceutical industry where larger pharmaceutical companies like Gilead form alliances and take significant equity stakes in smaller, innovative biotech firms like Arcus Biosciences. This strategy allows large pharma to access promising early-stage pipelines and technologies, while providing smaller biotechs with crucial funding, development expertise, and market access, thereby de-risking their R&D efforts and accelerating drug development.

Comparison to Industry Standards

• This document primarily details changes in beneficial ownership and strategic investment, rather than operational or financial performance metrics, making direct comparisons to industry-standard financial benchmarks challenging.
• However, the strategic partnership model, where a major pharmaceutical company (Gilead) takes a substantial equity stake and secures collaboration rights with a clinical-stage biotechnology company (Arcus Biosciences), is a well-established and common practice in the biopharmaceutical industry. This type of alliance is often seen as a validation of the smaller company's scientific platform and pipeline potential.
• The lock-up agreement is a standard practice in public offerings to ensure market stability post-issuance.

Corporate Governance

Related Party Transactions

• Gilead Sciences' multiple purchases of Arcus Biosciences' common stock (2020 Public Offering, Initial Purchase, Second Purchase, Third Purchase, Fourth Purchase, and the most recent Public Offering) are related party transactions due to their strategic collaboration and significant ownership.
• The Option, License and Collaboration Agreement between Gilead and Arcus is a related party transaction.
• The various Common Stock Purchase Agreements (including the Third Amended and Restated Purchase Agreement) and the Amended and Restated Investor Rights Agreement are related party transactions.

Stakeholder Impact

• Shareholders: Experience dilution from public offerings but benefit from the strong validation and financial stability provided by a major strategic investor like Gilead, potentially leading to increased investor confidence and long-term value.
• Employees: Benefit from increased stability and resources due to the strategic partnership, potentially leading to enhanced R&D capabilities and job security.
• Customers/Patients: Potential for accelerated development and commercialization of new medicines through the collaboration, addressing unmet medical needs.
• Creditors: Enhanced financial stability of Arcus Biosciences due to Gilead's investment may improve creditworthiness.
• Suppliers: Potential for increased business as Arcus's operations expand with Gilead's support.

Next Steps

• Gilead may, at its option, purchase additional shares from Arcus Biosciences to maintain or increase its ownership up to 35% of the then-outstanding common stock over the next five years.
• The ongoing collaboration between Gilead and Arcus Biosciences regarding clinical programs is expected to continue.

Key Dates

Recommendation

Keywords

Gilead Sciences, Arcus Biosciences, Schedule 13D, beneficial ownership, strategic investment, biotechnology, pharmaceuticals, collaboration agreement, public offering, lock-up agreement, equity agreements, option shares